Cumulative updating approved biopharmaceuticals 1 on 1 free naked chat
Exp into channel sales & distribution Responsible for increasing the market penetration of BI products and achieve the sales targets for specific area. Attend meetings and keep minutes Receive and screen phone calls and redirect them when appropriate Handle and prioritize all outgoing or incoming correspondence Management and execution of routine HR matters such as salary administration, timely deposit of statutory dues etc.Also build relationships and grow BI brand by engaging the opinion leaders in the specified area Directs the activities of an analytical development group in the research and/or development of an organization's products, projects and programs. Co-ordination with outsourcing agencies like Ma Foi & Team Lease, Proper maintenance of HR records such as, Personal files Proactive development of marketing and promotional mix to meet brand objectives and customer needs."This positive CHMP opinion is a significant milestone for patients impacted by this painful, chronic disease as there are currently no approved medications available for adolescents to treat it." Hidradenitis suppurativa, sometimes referred to as "acne inversa" by dermatologists, is a painful, debilitating, chronic inflammatory skin disease estimated to affect 1 – 4 percent of the world's population.HUMIRA EU Therapeutic Indications HUMIRA is approved for use in adults with moderate to severe active and progressive rheumatoid arthritis, severe active ankylosing spondylitis (AS), severe axial spondyloarthritis without radiographic evidence of AS, moderate to severe chronic plaque psoriasis, active and progressive psoriatic arthritis, moderately to severely active Crohn's disease, moderately to severely active ulcerative colitis, active moderate to severe hidradenitis suppurativa and non-infectious intermediate, posterior and panuveitis in adults.
Most sectors trade in the green this morning with energy (-0.1%), health care (-0.1%), and materials (-0.1%) being the only laggards.
CYTR) a biopharmaceutical research and development company specializing in oncology, today announced an update on the regulatory pathway for a New Drug Application (NDA) submission for aldoxorubicin in soft tissue sarcomas (STS)." data-reactid="11"LOS ANGELES, June 8, 2017 /PRNewswire/ -- Cyt Rx Corporation (CYTR) a biopharmaceutical research and development company specializing in oncology, today announced an update on the regulatory pathway for a New Drug Application (NDA) submission for aldoxorubicin in soft tissue sarcomas (STS).
The Company plans to submit a rolling NDA under section 505(b)(2) to the FDA for aldoxorubicin as a treatment for STS.
Qualys expects the transaction to close during the third quarter of 2017." data-reactid="24" am Qualys to acquire Nevis Networks (QLYS) : .
Qualys expects the transaction to close during the third quarter of 2017. am On The Wires (: WIRES) :" data-reactid="25" am Threshold Pharma to conduct a reverse split (THLD) : The reverse stock split will become effective at p.m. Subject to the satisfaction of customary closing conditions, the closing of the merger with Molecular Templates is expected to occur shortly following the effectiveness of the reverse stock split. am S&P futures vs fair value: 8.80. (: WRAPX) : Apple's (AAPL 149.10, 0.37) latest earnings report, which will be released following the closing bell.